Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309016805> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4309016805 endingPage "vii61" @default.
- W4309016805 startingPage "vii60" @default.
- W4309016805 abstract "Abstract INTRODUCTION Immunotherapy is limited in efficacy for glioblastoma (GBM). The objective of this study was to evaluate the efficacy and immune effects of the pp65 mRNA dendritic cell (DC) vaccine with the use of lysosomal-associated membrane protein (LAMP) in two different formulations (full-length (fl) and short-length (sh). METHODS Patients who underwent resection of newly diagnosed GBM were enrolled and randomized to one of 3 arms: Arm 1) pp65-shLAMP mRNA DC with GM-CSF, Arm 2) pp65-flLAMP mRNA DC with GM-CSF, Arm 3) Unpulsed peripheral blood mononuclear cells (PBMC). After surgery, patients underwent leukapheresis for PBMC isolation and vaccines generation. Patients were treated with standard radiation and temozolomide followed by dose intensified adjuvant temozolomide at 75-100 mg/m2 x 21 days (aged less than 70) or standard dose at 150-200 mg/m2 x 5 days (patients 70 and older). Immunization started days 22-24 of cycle #1 with vaccines 1-3 delivered at 2 week intervals. All patients received tetanus-toxoid booster prior to vaccine 1. Patients continued to receive monthly vaccines for up to 10 vaccines with tetanus-diphtheria toxoid skin prep prior to vaccines 3, 6 and 9 (arms 1 and 2). Safety, efficacy and immune labs were evaluated. RESULTS Overall DC vaccines were well-tolerated with 2 SAEs possibly attributed to DC vaccination that met criteria as DLTs. Of recorded grade 2 or lower AEs, 2 were possibly attributable to DC vaccination. One patient was removed from the study due to failure to produce DC vaccines that met QA/QC release criteria. CONCLUSION In a large randomized and blinded patient cohort, delivery of CMV LAMP pp65 mRNA DC vaccines is feasible and safe in a multi-institutional setting. The primary endpoint of survival will be analyzed at the conclusion of the study." @default.
- W4309016805 created "2022-11-20" @default.
- W4309016805 creator A5030121667 @default.
- W4309016805 creator A5037596103 @default.
- W4309016805 creator A5041466780 @default.
- W4309016805 creator A5071001644 @default.
- W4309016805 creator A5071832983 @default.
- W4309016805 creator A5085549922 @default.
- W4309016805 creator A5087959258 @default.
- W4309016805 date "2022-11-01" @default.
- W4309016805 modified "2023-09-27" @default.
- W4309016805 title "CTIM-07. PHASE II RANDOMIZED, BLINDED, PLACEBO-CONTROLLED TRIAL TESTING PP65 CMV MRNA DENDRITIC CELL VACCINE AND TETANUS-DIPHTHERIA TOXOID FOR NEWLY DIAGNOSED GBM (ATTAC II, NCT02465268)" @default.
- W4309016805 doi "https://doi.org/10.1093/neuonc/noac209.239" @default.
- W4309016805 hasPublicationYear "2022" @default.
- W4309016805 type Work @default.
- W4309016805 citedByCount "1" @default.
- W4309016805 countsByYear W43090168052023 @default.
- W4309016805 crossrefType "journal-article" @default.
- W4309016805 hasAuthorship W4309016805A5030121667 @default.
- W4309016805 hasAuthorship W4309016805A5037596103 @default.
- W4309016805 hasAuthorship W4309016805A5041466780 @default.
- W4309016805 hasAuthorship W4309016805A5071001644 @default.
- W4309016805 hasAuthorship W4309016805A5071832983 @default.
- W4309016805 hasAuthorship W4309016805A5085549922 @default.
- W4309016805 hasAuthorship W4309016805A5087959258 @default.
- W4309016805 hasBestOaLocation W43090168051 @default.
- W4309016805 hasConcept C10205521 @default.
- W4309016805 hasConcept C126322002 @default.
- W4309016805 hasConcept C137061746 @default.
- W4309016805 hasConcept C185592680 @default.
- W4309016805 hasConcept C202751555 @default.
- W4309016805 hasConcept C203014093 @default.
- W4309016805 hasConcept C22070199 @default.
- W4309016805 hasConcept C2777351567 @default.
- W4309016805 hasConcept C2777371436 @default.
- W4309016805 hasConcept C2777389519 @default.
- W4309016805 hasConcept C2777863537 @default.
- W4309016805 hasConcept C2779841045 @default.
- W4309016805 hasConcept C28328180 @default.
- W4309016805 hasConcept C509974204 @default.
- W4309016805 hasConcept C54355233 @default.
- W4309016805 hasConcept C55493867 @default.
- W4309016805 hasConcept C71924100 @default.
- W4309016805 hasConcept C86803240 @default.
- W4309016805 hasConcept C90924648 @default.
- W4309016805 hasConceptScore W4309016805C10205521 @default.
- W4309016805 hasConceptScore W4309016805C126322002 @default.
- W4309016805 hasConceptScore W4309016805C137061746 @default.
- W4309016805 hasConceptScore W4309016805C185592680 @default.
- W4309016805 hasConceptScore W4309016805C202751555 @default.
- W4309016805 hasConceptScore W4309016805C203014093 @default.
- W4309016805 hasConceptScore W4309016805C22070199 @default.
- W4309016805 hasConceptScore W4309016805C2777351567 @default.
- W4309016805 hasConceptScore W4309016805C2777371436 @default.
- W4309016805 hasConceptScore W4309016805C2777389519 @default.
- W4309016805 hasConceptScore W4309016805C2777863537 @default.
- W4309016805 hasConceptScore W4309016805C2779841045 @default.
- W4309016805 hasConceptScore W4309016805C28328180 @default.
- W4309016805 hasConceptScore W4309016805C509974204 @default.
- W4309016805 hasConceptScore W4309016805C54355233 @default.
- W4309016805 hasConceptScore W4309016805C55493867 @default.
- W4309016805 hasConceptScore W4309016805C71924100 @default.
- W4309016805 hasConceptScore W4309016805C86803240 @default.
- W4309016805 hasConceptScore W4309016805C90924648 @default.
- W4309016805 hasIssue "Supplement_7" @default.
- W4309016805 hasLocation W43090168051 @default.
- W4309016805 hasOpenAccess W4309016805 @default.
- W4309016805 hasPrimaryLocation W43090168051 @default.
- W4309016805 hasRelatedWork W1991450358 @default.
- W4309016805 hasRelatedWork W2015493606 @default.
- W4309016805 hasRelatedWork W2085340571 @default.
- W4309016805 hasRelatedWork W2130588157 @default.
- W4309016805 hasRelatedWork W2473013351 @default.
- W4309016805 hasRelatedWork W2970907102 @default.
- W4309016805 hasRelatedWork W2979956564 @default.
- W4309016805 hasRelatedWork W41506990 @default.
- W4309016805 hasRelatedWork W4313289890 @default.
- W4309016805 hasRelatedWork W4379375216 @default.
- W4309016805 hasVolume "24" @default.
- W4309016805 isParatext "false" @default.
- W4309016805 isRetracted "false" @default.
- W4309016805 workType "article" @default.